Petros Grivas, MD, PhD, University of Washington School of Medicine, Seattle, WA discusses the results from the Phase Ib trial (NCT04501094) of bintrafusp alfa (BA) for the treatment of pretreated, metastatic urothelial cancer. BA, designed to target the TGF-β pathway and PD-L1, was tested in 25 patients. At the data cutoff, the confirmed response rate was 20%, with a median progression-free survival of 1.8 months. The trial's accrual was stopped due to insufficient evidence of superior benefits compared to existing treatments. Notable adverse events were observed, and while further development of BA in this context was discontinued, future studies may investigate TGF-β pathway inhibition in urothelial cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть